(Q24649764)

English

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy

scientific article

In more languages

Statements

scholarly article

0 references

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ping Zhou

1

0 references

Raymond L Comenzo

2

0 references

Adam B Olshen

3

0 references

Ezio Bonvini

4

0 references

Scott Koenig

5

0 references

Peter G Maslak

6

0 references

Martin Fleisher

7

0 references

James Hoffman

8

0 references

Suresh Jhanwar

9

0 references

James W Young

10

0 references

Stephen D Nimer

11

0 references

Adam M Boruchov

12

0 references

language of work or name

0 references

publication date

1 April 2008

0 references

0 references

111

0 references

7

0 references

3403-6

0 references

Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

7 April 2017

The antiinflammatory activity of IgG: the intravenous IgG paradox

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

7 April 2017

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

7 April 2017

Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Managing systemic light-chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Antibodies, Fc receptors and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Transplantation for amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 September 2017

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 November 2018

Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 November 2018

Expression of functional activating and inhibitory Fcgamma receptors on human B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 November 2018

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275009

28 November 2018

Expression of CD52 on plasma cells in plasma cell proliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/18216299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The plasma cell labeling index: a valuable tool in primary systemic amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18216299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18216299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FcγRIIb controls bone marrow plasma cell persistence and apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18216299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18216299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2007-11-125526

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24649764&oldid=1587268981"